DelNova to Advance ReViVox™, A Groundbreaking Rescue Drug to Reverse Botulinum Toxin Neuromodulator Complications

DelNova announces advances in the development of the First ever product to reverse complications arising from botulinum toxins, such as BOTOX®, Dysport®, XEOMIN®, and Jeuveau®, US patent and launch of STARTENGINE equity crowdfunding. SAN DIEGO and CHICAGO, April 1, 2022 /PRNewswire/ –…

Click here to view original post